We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

37 hedge funds and large institutions have $936K invested in Cardiff Oncology in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $797K → $936K (+$139K)

0% less ownership

Funds ownership: 0.07% → 0.07% (-0%)

3% less funds holding

Funds holding: 38 → 37 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

Holders
37
Holders Change
-1
Holders Change %
-2.63%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$72.1K
2
Renaissance Technologies
Renaissance Technologies
New York
+$44.1K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$15.3K
4
VF
Virtu Financial
New York
+$11.7K
5
Jane Street
Jane Street
New York
+$4.14K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$34K
2
CGA
Crescent Grove Advisors
Illinois
-$26K
3
TSS
Two Sigma Securities
New York
-$25K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$8.41K
5
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$344K +$72.1K +2,923 +27%
BlackRock
2
BlackRock
New York
$140K -$1.73K -70 -1%
EP
3
Elkhorn Partners
Nebraska
$101K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$48K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$45K +$44.1K +1,787 New
PFS
6
Prospera Financial Services
Texas
$44K – – –
VF
7
Virtu Financial
New York
$37K +$11.7K +475 +48%
California Public Employees Retirement System
8
California Public Employees Retirement System
California
$27K – – –
CAPTRUST Financial Advisors
9
CAPTRUST Financial Advisors
North Carolina
$22K – – –
Northern Trust
10
Northern Trust
Illinois
$20K – – –
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$16K +$15.3K +622 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
$11K -$8.41K -341 -43%
Barclays
13
Barclays
United Kingdom
$9K – – –
MSTVIM
14
Messner & Smith Theme Value Investment Management
California
$8K -$345 -14 -4%
RJA
15
Raymond James & Associates
Florida
$8K -$320 -13 -4%
Bank of Montreal
16
Bank of Montreal
Ontario, Canada
$8K – – –
UBS Group
17
UBS Group
Switzerland
$8K +$2.86K +116 +61%
IAA
18
Independent Advisor Alliance
North Carolina
$6K – – –
PCM
19
Princeton Capital Management
New Jersey
$6K – – –
Goldman Sachs
20
Goldman Sachs
New York
$5K -$99 -4 -2%
State Street
21
State Street
Massachusetts
$5K – – –
PWAG
22
Polaris Wealth Advisory Group
California
$4K +$4.12K +167 New
Jane Street
23
Jane Street
New York
$4K +$4.14K +168 New
Bank of America
24
Bank of America
North Carolina
$2K – – –
MAM
25
Meeder Asset Management
Ohio
$2K – – –
1
2

CRDF Hedge Fund Activity: Q1 2018 in Review

37 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2018, worth a combined $936K — up 17% from $797K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CRDF and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 4 added.

The largest buyer was Vanguard Group, adding an estimated $72.1K. The largest seller was Millennium Management, exiting entirely with an estimated $34K sold.

  • 37 institutional investors held Cardiff Oncology (CRDF) as of Q1 2018, down from 38 in Q4 2017.
  • Funds reported $936K of Cardiff Oncology stock for Q1 2018, up 17% quarter-over-quarter.
  • 5 funds opened new Cardiff Oncology positions in Q1 2018 and 6 closed out, a net change of -1 holder.
  • The largest Cardiff Oncology buyer in Q1 2018 was Vanguard Group, an estimated $72.1K added.
  • The largest Cardiff Oncology seller in Q1 2018 was Millennium Management, an estimated $34K sold.

Based on aggregated 13F filings for Q1 2018.